Prescreening Study to Identify Potential Participants for ACDN-01 Clinical Trials

Description

This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.

Conditions

Stargardt Disease, Stargardt Disease 1, Cone Rod Dystrophy, Juvenile Macular Degeneration

Talk to us

Study Overview

On this page

Study Details

Study overview

This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.

Prescreening Study to Identify Potential Participants With ABCA4-related Retinopathy for ACDN-01 Clinical Trials

Prescreening Study to Identify Potential Participants for ACDN-01 Clinical Trials

Condition
Stargardt Disease
Intervention / Treatment

-

Contacts and Locations

San Francisco

University of San Francisco, San Francisco, California, United States, 94158

Gainesville

Vitreo Retinal Associates, Gainesville, Florida, United States, 32607

Baltimore

Wilmer Eye Institute at John Hopkins, Baltimore, Maryland, United States, 21218

Boston

Massachusetts Eye and Ear, Boston, Massachusetts, United States, 02114

Ann Arbor

University of Michigan Kellogg Eye Center, Ann Arbor, Michigan, United States, 48105

Cincinnati

Cincinnati Eye Institute, Cincinnati, Ohio, United States, 45245

Dallas

Retina Foundation of Texas, Dallas, Texas, United States, 75382

Houston

Retina Consultants of Texas, Houston, Texas, United States, 77401

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Presence of mutations in the ABCA4 gene
  • * ABCA4 retinopathy phenotype (Stargardt disease type 1 or cone-rod dystrophy)
  • * The presence of pathogenic or likely pathogenic mutations in other genes known to cause cone-rod dystrophy or Stargardt maculopathy
  • * Retinal disease other than ABCA4-related retinopathy
  • * Presence of a medical condition (systemic or ophthalmic), psychiatric condition, including substance abuse disorder, or physical examination or laboratory finding that may in the opinion of the principal investigator and sponsor preclude adherence to the scheduled study visits, safe participation in the study, or affect the results of the study.

Ages Eligible for Study

5 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Ascidian Therapeutics, Inc,

Alia Rashid, STUDY_DIRECTOR, Ascidian Therapeutics

Study Record Dates

2030-08-31